This enhanced effect is believed to result from the reliance of KRAS G12C-mutant CRC tumors on EGFR signaling, suggesting that the dual inhibition of both pathways can provide a more effective therapeutic approach. The gene discussed is EGFR; the disease is colorectal carcinoma.